An increasing number of options are available for pharmaceutical companies seeking integrated scientific advice between regulators and health technology assessment (HTA) bodies, along with patient involvement, to optimize their evidence development program and ensure timely patient access to new, transformational medicines. As the array of opportunities for advice continues to evolve in terms of both scope and process, sponsors considering advice need continual, timely insight into how to select the best program(s) for their assets and which programs can be used based on program availability. Download our special feature to learn more.